文献速递产科母胎医学

囊性纤维化胎儿治疗的新兴数据转化

Translating Emerging Data for Fetal Treatment of Cystic Fibrosis.
PubMed 文献 · Prenat Diagn · 2026-02-18

本文综述了妊娠期囊性纤维化跨膜传导调节因子调节剂治疗(CFTRm)的应用,包括动物数据及已发表的人类病例。在20例产前接受CFTRm治疗的无症状携带者胎儿中,约三分之二的胎粪性肠梗阻超声表现消退;治疗开始较晚或存在胎粪性腹膜炎等并发症时未消退更常见。

要点

  • 妊娠期继续CFTRm与保持母体肺功能及良好产科结局相关。
  • 20例产前治疗胎儿中约三分之二胎粪性肠梗阻消退。
  • 胎粪性肠梗阻平均诊断孕24周,治疗开始平均孕31周。

核心结论

  • 在无症状携带者孕妇中,产前CFTRm治疗可使约三分之二胎儿胎粪性肠梗阻消退。

研究设计与样本

  • 综述了妊娠期CFTRm应用的动物数据及已发表人类病例,包括20例产前治疗的无症状携带者胎儿。

主要发现

  • 在20例产前接受CFTRm治疗的无症状携带者胎儿中,超声示胎粪性肠梗阻约三分之二消退。
  • 若干报告描述外分泌胰腺功能保持或临界,汗氯水平低于预期。
  • 治疗开始较晚或存在胎粪性腹膜炎等并发症时,胎粪性肠梗阻未消退更常见。
  • 胎粪性肠梗阻平均诊断孕24周,治疗开始平均孕31周。

临床怎么用

  • 妊娠期CF患者继续CFTRm可能保持母体肺功能并改善产科结局。
  • 对无症状携带者胎儿产前CFTRm治疗需权衡胎粪性肠梗阻消退可能性与开始时机。

局限性

  • CF基金会PROTECT研讨会指出知识缺口包括产前诊断与治疗最佳时机、胎儿药代动力学、神经发育安全性、最小有效剂量及预防产后撤药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We reviewed the contemporary use of cystic fibrosis transmembrane conductance regulator modulator therapy (CFTRm) during pregnancy, including animal data and published human cases involving unaffected pregnant CF (heterozygote) carriers with a prenatal diagnosis of fetal cystic fibrosis (CF). In pregnant individuals with CF, continuation of CFTRm is associated with preserved maternal pulmonary function comparable to nonpregnant peers and favorable obstetrical outcomes. CFTRm crosses the placenta readily, appears at low levels in breastmilk, and concerns for cataracts from animal models have not been translated clinically. Among 20 reported fetal cases treated prenatally with CFTRm in unaffected carrier individuals, ultrasound findings of meconium ileus (MI) resolved in approximately two-thirds of cases. Several reports describe preserved or borderline exocrine pancreatic function and lower-than-expected sweat chloride levels. Nonresolution of MI was more common when therapy began later in gestation or in the presence of complications such as meconium peritonitis. MI was diagnosed at a mean gestational age of 24 weeks, while treatment began at 31 weeks, reflecting delays in both diagnosis and insurance coverage. The CF Foundation PROTECT Workshop identified key knowledge gaps, including optimal timing of prenatal diagnosis and therapy, fetal pharmacokinetics, neurodevelopmental safety, minimal effective dosing, and prevention of postnatal withdrawal.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Zaretsky MV, Blumenfeld YJ, Szentpetery SS, et al. Translating Emerging Data for Fetal Treatment of Cystic Fibrosis. Prenat Diagn. 2026. PMID: 41705887. doi:10.1002/pd.70098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。